Welcome to Méridian Strategic Advisors

Healthcare Innovation Capital for Late-Stage Companies Ready to Launch

Méridian connects exceptional longevity and quality of life technologies with the institutional capital and regulatory expertise needed to reach patients.

The hardest part of bringing medical innovation to market isn't proving the science. It's navigating the final 10%: funding clinical trials, securing FDA clearance, and executing a commercialization strategy that institutional investors will back.

We work exclusively with late-stage biotech and life sciences companies that have proven their technology, assembled their teams, and established their intellectual property protection. If you're approximately 90% complete and need strategic capital to fund your pivotal trials and navigate regulatory approval, we can help.

Méridian maintains relationships with institutional investors and family offices who receive pre-vetted deal flow on a membership basis. We take on only 3-4 active clients at a time, ensuring you receive our full strategic attention during the critical commercialization phase.

Our approach is straightforward: comprehensive due diligence, long-term alignment through equity participation, and direct access to institutional capital that understands late-stage life sciences investment.

Clinical Trial Funding

We secure institutional capital specifically for Phase II/III clinical trials and pivotal studies that support FDA submissions. Our investor network understands late-stage biotech risk profiles and the capital requirements for regulatory approval.

Regulatory Strategy

Clinical Trial Funding

We help companies navigate FDA clearance pathways (510(k), PMA, IND), establish relationships with clinical trial sites, and build commercialization strategies that demonstrate clear market access to institutional investors.

Institutional Access

Clinical Trial Funding

Institutional Access

Our membership-based investor network receives pre-vetted late-stage opportunities. We take 50% of success fees in equity to ensure long-term alignment, and we only work with 3-4 companies at a time.

Why Choose Us?

How Méridian Works

Méridian operates at the critical inflection point between validated science and commercial scale. We raise capital for late-stage biotech and life sciences companies developing longevity and quality of life technologies, and we build commercialization strategies that address regulatory pathways, clinical trial execution, and market access.

According to BIO (Biotechnology Innovation Organization), only 1 in 10 drug candidates entering clinical trials ultimately receives FDA approval, and the average cost to bring a new drug to market now exceeds $2.6 billion. The highest failure rate occurs not in early R&D, but during Phase III trials and the regulatory approval process where companies run out of capital or lack the strategic relationships to complete commercialization.

This is where Méridian adds value. We work exclusively with companies that have moved past the science risk—those with established intellectual property protection, proven technology platforms, assembled management teams, and approximately 90% development completion. Our clients need strategic capital to fund their pivotal clinical trials, navigate FDA approval processes, and execute go-to-market strategies that institutional investors will support.

Our founder brings over 25 years of experience at the intersection of institutional investment and complex transactions, including a background in investment advisory at RBC Dominion Securities. We maintain FINRA licensing (Series 82: Private Securities Offerings Representative) and broker-dealer affiliation, providing the regulatory framework necessary for institutional capital raises in the life sciences sector.

What Sets Méridian Apart

SELECTIVE CLIENT BASE

COMPREHENSIVE DUE DILIGENCE

We take on only 3-4 active clients at any time, with annual capacity for approximately 12-15 companies. This selective approach ensures comprehensive due diligence and full strategic attention during your critical commercialization phase. Our clients are sophisticated founders who understand that access to institutional capital requires rigorous vetting and strategic positioning.

COMPREHENSIVE DUE DILIGENCE

Before presenting any opportunity to our investor network, we conduct extensive due diligence that addresses: intellectual property protection and freedom to operate analysis, regulatory pathway assessment and FDA approval timeline, clinical trial design and endpoint validation, market access and reimbursement strategy, management team capabilities and track record, competitive landscape and differentiation analysis, and capital efficiency and use of proceeds planning.

LONG-TERM EQUITY ALIGNMENT

COMPREHENSIVE DUE DILIGENCE

INSTITUTIONAL INVESTOR NETWORK

We take 50% of our success fees in equity rather than cash, ensuring we're incentivized for your long-term commercial success, not just closing the capital raise. This equity alignment demonstrates our confidence in your technology and creates a partnership that extends well beyond initial funding.

INSTITUTIONAL INVESTOR NETWORK

We maintain relationships with institutional investors and family offices who receive pre-vetted late-stage biotech opportunities on a membership basis. These investors understand late-stage life sciences risk profiles and have the capital capacity to fund multi-year clinical trial programs and regulatory submissions.

ETHICAL STANDARDS

INSTITUTIONAL INVESTOR NETWORK

ETHICAL STANDARDS

We're uncompromising on ethical behavior. We won't pursue capital from investors whose values don't align with responsible life sciences innovation, and we won't represent companies whose technology doesn't meet our rigorous scientific and commercial viability standards.